Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Open in API
Filings indexed 2,379 across all filing types
Latest filing 2024-05-20 M&A Activity
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 20, 2024, reporting the completion of an acquisition (Alpine Immune Sciences) by Vertex Pharmaceuticals. It details the acquisition event, references the merger agreement, and includes forward-looking statements and risk factors. The document is a current report on a significant corporate event, specifically an acquisition, rather than a full annual or quarterly report, earnings release, or other types of filings. The content aligns with announcements related to mergers and acquisitions activity. Therefore, the appropriate classification is 'M&A Activity' (TAR). The document length (7025 characters) and content confirm it is a substantive filing, not just an announcement of a report or a certification.
2024-05-20 English
SC TO-T/A Filing
Merger & Acquisition Classification · 100% confidence The document is a Schedule TO filing, which is a Tender Offer Statement under the Securities Exchange Act of 1934. It is an amendment (No. 3) to the Schedule TO related to a third-party tender offer by Adams Merger Sub, Inc., a subsidiary of Vertex Pharmaceuticals, to acquire Alpine Immune Sciences, Inc. The document details the expiration of the offer, the number of shares tendered, acceptance for payment, consummation of the acquisition through a merger, and the subsequent delisting and deregistration of the shares. This type of filing is specifically related to merger and acquisition activity, including tender offers and related disclosures. Therefore, the appropriate classification is Merger & Acquisition (MA). The document is substantive and not merely an announcement or certification, so it is not classified as RNS or RPA.
2024-05-20 English
FORM 4
Director's Dealing
2024-05-17 English
FORM 4
Director's Dealing
2024-05-17 English
FORM 4
Director's Dealing
2024-05-17 English
FORM 4
Director's Dealing
2024-05-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.